| You are here: Home: BCU 5|2002: Eleftherios P Mamounas, MD - Select Publications
Select publications
Neoadjuvant chemotherapy
NSABP. The effect of primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27. Breast Cancer Res Treat 2001;Abstract 5.
Aapro MS. Neoadjuvant therapy in breast cancer: Can we define its role? Oncologist 2001;6 Suppl 3:36-9. Abstract
Barni S et al. Cisplatin-epirubicin-vinorelbine: A new neoadjuvant chemotherapy for stage T2-3/N0-2 breast cancer patients. Breast Cancer Res Treat 2001;Abstract 515.
Buchholz TAet al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002;20(1):17-23. Abstract
Burstein HJ et al. Preoperative trastuzumab (T) and paclitaxel (P) for HER2 overexpressing (HER2+) stage II/III breast cancer: Clinical, pathological and serological findings. Breast Cancer Res Treat 2001;Abstract 507.
Chollet P et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86(7):1041-6. Abstract
Colleoni M et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001;19:4141-9. Abstract
El-Didi MH et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 2000;30:249-54. Abstract
Fumoleau P et al. A randomized phase II study of 4 or 6 cycles of Adriamycin/Taxol (paclitaxel) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 2001;Abstract 508.
Jackisch C et al. Dose-dense weekly (8 weeks) vs. sequential (24 weeks) neoadjuvant chemotherapy with adriamycin/cyclophosphamide and docetaxel in operable breast cancer (T2-3, N0-2, M0) — Interim analysis of the Geparduo trial. Breast Cancer Res Treat 2001;Abstract 509.
Jakesz R. Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Study Group (ABCSG) Trial 7. Proc ASCO 2001; Abstract125.
Krag D et al. The sentinel node in breast cancer — a multicenter validation study. N Engl J Med 1998;339:(14)941-6. Abstract
Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001;28:389-99. Abstract
Petit T et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001;7:1577-81. Abstract
Sanchez-Rovira P et al. HER2-status as a predictive factor for pathological complete response in primary breast cancer patients treated with gemcitabine-adriamycin-taxol as neoadjuvant treatment. Breast Cancer Res Treat 2001;Abstract 240.
Sartor CI et al. Low rate of ipsilateral breast tumor recurrence for patients with T3/T4 tumors treated with neoadjuvant chemotherapy followed by breast-conserving therapy. Breast Cancer Res Treat 2001;Abstract 143.
Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am J Surg 2001;182:341-6. Abstract
Smith IC et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20(6):1456-66. Abstract
Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001;12 Suppl 1:S25-9. Abstract
van der Hage JA et al. Improved survival after one course of perioperative chemotherapy in early breast cancer patients. Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Eur J Cancer 2001;37:2184-93. Abstract
van der Hage JA et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224-37. Abstract
Local recurrence
Bartelink H et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-87. Abstract
Buchholz TA et al. Impact of systemic treatment on local control for patients with lymph nodenegative breast cancer treated with breast-conservation therapy. J Clin Oncol 2001;19:2240-6. Abstract
Cowen D et al. Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys 2000;47:305-12. Abstract
della Rovere GQ, Benson JR. Ipsilateral local recurrence of breast cancer: Determinant or indicator of poor prognosis? Lancet Oncol 2002;3:183-7. Abstract
Doyle T et al. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys 2001;51:74-80. Abstract
Elkhuizen PH et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 2000;18:1075-83. Abstract
Freedman GM, Fowble BL. Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology (Huntingt) 2000;14:1561-81; discussion 1581-2, 1582-4. Abstract
Harms W et al. Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrences. Int J Radiat Oncol Biol Phys 2001;49:205-10. Abstract
Horiguchi J et al. Immunohistochemical study on primary and recurrent tumors in patients with local recurrence in the conserved breast. Oncol Rep 2000;7:295-8. Abstract
Janni W et al. Matched pair analysis of survival after chest-wall recurrence compared to mammary recurrence: A long-term follow up. J Cancer Res Clin Oncol 2001;127:455-62. Abstract
Janni W et al. Radiotherapy of the chest wall following mastectomy for early-stage breast cancer: Impact on local recurrence and overall survival. Int J Radiat Oncol Biol Phys 2000;48:967-75. Abstract
King TA et al. Biopsy technique has no impact on local recurrence after breast-conserving therapy. Breast J 2001;7:19-24. Abstract
Lohrisch C et al. Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer. J Clin Oncol 2000;18:2828-35. Abstract
Marret H et al. Histologic multifocality is predictive of skin recurrences after conserving treatment of stage I and II breast cancers. Breast Cancer Res Treat 2001;68:1-8. Abstract
McCready DR et al. Factors associated with local breast cancer recurrence after lumpectomy alone: Postmenopausal patients. Ann Surg Oncol 2000;7:562-7. Abstract
Park CC et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 2000;18:1668-75. Abstract
Simmons RM et al. Recurrence rates in patients with central or retroareolar breast cancers treated with mastectomy or lumpectomy. Am J Surg 2001;182:325-9. Abstract
Tartter PI et al. Lumpectomy margins, reexcision, and local recurrence of breast cancer. Am J Surg 2000;179:81-5. Abstract
Voogd AC et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97. Abstract
|
